Navigation Links
Topokine Commences Phase 2 Clinical Trial of XAF5 Gel to Reduce Submental Fat
Date:11/19/2013

BOSTON, Nov. 19, 2013 /PRNewswire-iReach/ -- Topokine Therapeutics has initiated dosing in a Phase 2, randomized controlled clinical trial of XAF5 Gel for reduction of excess submental fat, commonly known as "double chin." XAF5 Gel is a proprietary skin formulation of a compound already known to reduce fat around the human eye.  Study participants are applying XAF5 Gel or placebo once a night to skin under the chin.

"Patients are increasingly interested in non-invasive therapies to rejuvenate the face," said Jeffrey S. Dover, MD, FRCPC, a nationally recognized dermatologist and member of the Topokine's Scientific Board of Advisors.  "If approved, XAF5 Gel would provide a convenient topical medication that reduces submental fat."

XAF5 is a small molecule that induces a G protein-coupled cascade in adipocytes to reduce cellular lipid content and differentiation.  Daily administration of XAF5 reduces fat around the human eye and in five laboratory models.  The technology was first conceived by ophthalmologists at the Massachusetts Eye and Ear Infirmary / Harvard Medical School Department of Ophthalmology.

The Phase 2 study follows positive data from a 6-week Phase 1 clinical trial completed in April 2013.  In that randomized, double-blind, placebo-controlled study, 32 healthy men and women applied XAF5 Gel or placebo once a night to a 100 cm2 area of abdominal skin.  The study met its pre-specified primary safety and tolerability endpoint at all doses.  The only side effects were mild, temporary skin redness or itch, which occurred at similar rates with placebo.  Exploratory CT scans showed a dose-dependent reduction in fat volume under treated skin as compared to contralateral untreated skin.

 "We are excited to advance our XAF5 Gel program into Phase 2," said Topokine's Chief Scientific Officer, Michael Singer, MD, PhD.  "Our research shows that patients would prefer a topical fat-reducing medication over therapies that cut or puncture the skin, which are the only treatments currently available.  The submental region is one of several body areas that we plan to target." 

About Topokine

Topokine Therapeutics is a clinical-stage biotechnology company developing topical prescription medications for non-invasive contouring of the face and body.  The company's lead program, XAF5 Gel, is a topical adipomodulatory product in Phase 2 clinical development for local reduction of excess subcutaneous fat.  Topokine's pipeline also includes XAF5 Ointment to treat steatoblepharon ("eye bags") and TAT4, a topical "filler" therapy to increase local tissue volume.

About Submental Fat

The area under the chin, also called the submental region, is an important determinant of facial attractiveness and youthfulness. Excess submental fat is very common and contributes to the appearance known as "double chin."  People with excess submental fat are more likely to report feeling self-conscious or appearing older or overweight.  Currently, the only available therapies to reduce submental fat require cutting or puncturing the skin.

Forward-Looking Statements

This press release contains forward-looking statements regarding the development of XAF5 Gel.  These statements are based on Topokine's current beliefs and expectations, but actual results may differ.

Media Contact: Matt Burke, Topokine, 6033150618, matt.burke@topokine.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Topokine Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Topokine Announces Dosing of First Subject in a Phase I Clinical Trial of XAF5 Gel for Local Reduction of Subcutaneous Fat
2. GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM)
3. Lightlake Therapeutics Commences Two-Week Patient Trial for Treatment of Opioid Overdose with National Institute on Drug Abuse (NIDA)
4. Clinical Phase Ia Trial on MIV-711 Complete and Phase Ib Trial Commences
5. Perrigo Receives FDA Approval And Commences Launch Of Morphine Sulfate 100ml/5% Oral Solution
6. Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
7. Surprise: Viruses Can Cause Disease during Latent Phase; New Evidence Supports Microcompetition Theory
8. RXi Pharmaceuticals Announces the Start of Their First Phase 2 Study with RXI-109 for Treatment of Hypertrophic Scars in Conjunction with Scar Revision Surgery
9. Omeros to Present Data from OMS302 Phase 3 Clinical Program at the American Academy of Ophthalmology Annual Meeting
10. Pfenex Inc. Awards Paragon Bioservices a Contract for cGMP Manufacturing of its Recombinant Protective Antigen (rPA), for Phase 1 Clinical Trial of its Anthrax Vaccine
11. Cellular Biomedicine Group Announces Completion of Patient Treatment for Phase I/IIa Clinical Trial for Treatment of Knee Osteoarthritis (KOA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... SEATTLE , Nov. 30, 2016  The ... Allen Cell Collection: the first publicly available collection ... stem cells that target key cellular structures with ... Medical Research, these powerful tools are a crucial ... cells to better understand what makes human cells ...
(Date:11/30/2016)... November 2016   Merck , ein ... Unterzeichnung einer Reihe von Vereinbarungen mit Evotec ... AG Screeningleistungen für Mercks Palette genetischer Reagenzien ... auf diese Bibliotheken in Kombination mit Evotecs ... Weg zur Ermittlung und Erforschung neuer Arzneimitteltargets.    ...
(Date:11/30/2016)... Woburn, MA (PRWEB) , ... November 30, 2016 ... ... broadband light sources for advanced technology applications, introduces the 5th generation, ultra-bright, Laser-Driven ... the highly successful Laser-Driven Light Source (LDLS™) technology, the EQ-77 offers higher radiance ...
(Date:11/30/2016)... ... 30, 2016 , ... ProMIS Neurosciences (“ProMIS” or the “Company”), ... today announced that all five of its validated monoclonal antibody (mAb) therapeutic candidates ... prion-like forms of Amyloid beta (Aß) in vitro. , “We previously demonstrated that ...
Breaking Biology Technology:
(Date:6/22/2016)... 2016   Acuant , the leading ... has partnered with RightCrowd ® to ... Management, Self-Service Kiosks and Continuous Workforce Assurance. ... functional enhancements to existing physical access control ... with an automated ID verification and authentication ...
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
Breaking Biology News(10 mins):